What question did this study set out to answer?

To compare the clinical efficacy and safety profile of upadacitinib against dupilumab in adult patients with moderate-to-severe atopic dermatitis.

August 4, 2021JAMA DermatologyOpen Access

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

View Full Paper

Ask AI

Bookmark

To compare the clinical efficacy and safety profile of upadacitinib against dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Randomized clinical trial (ClinicalTrials.gov identifier NCT03738397) in adults presenting with moderate-to-severe atopic dermatitis.
Direct head-to-head active-comparator design evaluating systemic oral therapy against injectable biologic treatment.
Assessed comparative rates of skin lesion clearance and pruritus reduction between upadacitinib and dupilumab treatment arms.
Characterized treatment-emergent adverse event rates and laboratory abnormalities to evaluate comparative safety.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized trial reports comparative efficacy and safety outcomes of upadacitinib versus dupilumab in adults with atopic dermatitis, indicating distinct clinical profiles.

Abstract

ClinicalTrials.gov Identifier: NCT03738397.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Blauvelt et al. (2021) studied this question.

synapsesocial.com/papers/69d8ce83f39dfae3cad17e6b https://doi.org/10.1001/jamadermatol.2021.3023

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reports comparative efficacy and safety outcomes of upadacitinib versus dupilumab in adults with atopic dermatitis, indicating distinct clinical profiles.

Abstract

ClinicalTrials.gov Identifier: NCT03738397.

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading